A single course of newly approved Alzheimer's drug donanemab-azbt, the second medicine available in Japan targeting proteins in the brains of sufferers of the debilitating disease, will cost 3.08 ...

Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer's disease, reversing an earlier decision not to give it the green light.

The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at ...

It's the superstars of one of B&T's favourite channels - brand experience. Or brand experience with the free sample.

The state’s Democratic governor Kathy Hochul on Thursday confirmed a $9 daytime charge for drivers in certain areas of Manhattan would be implemented in January 2025, a lower toll than the $15 ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

"Biogen and Neomorph enter molecular glue degrader deal" was originally created and published by Pharmaceutical Technology, a ...

Trace Neuroscience aims to advance an RNA-binding therapy designed to preserve — and potentially improve — muscle function in ...

1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...

“It’s not just getting patients, it’s brand awareness,” he said ... Shibeshih Belachew, formerly of Biogen and now chief ...

Being one of the early entrants in the Alzheimer's treatment space in many international markets could allow Biogen to establish strong relationships with healthcare providers and build brand ...